<DOC>
	<DOC>NCT00577720</DOC>
	<brief_summary>To compare the efficacy 50 mg delayed-release risedronate tablet, dosed immediately after breakfast, to a 35 mg immediate-release tablet, administered according to labeling instructions.</brief_summary>
	<brief_title>Assess the Safety, Efficacy, and Pharmacokinetics of Immediate and Delayed Release Weekly Risedronate</brief_title>
	<detailed_description>To compare the efficacy, based on the bone turnover marker (BTM) serum Type I collagen C-telopeptide (CTx), of a 50 mg delayed-release risedronate tablet, administered immediately after a typical breakfast, to that of a 35 mg immediate-release tablet, administered according to labeling instructions (ie, at least 30 minutes prior to breakfast) in postmenopausal women after 13 weeks of treatment.</detailed_description>
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Etidronic Acid</mesh_term>
	<criteria>In generally good health, as determined by medical history, physical examination, and laboratory test results Postmenopausal greater than 2 years, naturally or surgically based on medical history. Used any of the following medications within 3 months prior to dosing or used any of the following medications for more than 1 month at any time within 6 months prior to dosing: oral or parenteral glucocorticoids (5 mg prednisone or equivalent/day) anabolic steroids estrogens (oral, skin patch, or gel), except for low dose vaginal products or insertable estrogen ring, selective estrogenreceptor modulators, or estrogenrelated drugs progestins calcitonin vitamin D supplements calcitriol, calcidiol, or alfacalcidol at any dose any bisphosphonate fluoride strontium parathyroid hormone, including teriparatide</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>